Compare Royal Bank of Canada (RY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs State Street SPDR S&P Biotech ETF — how do they compare? Royal Bank of Canada trades at $191.22 (market cap $262.99B), while State Street SPDR S&P Biotech ETF trades at $153.32 (market cap $10.11B). The key difference: Royal Bank of Canada is far larger — about 26× State Street SPDR S&P Biotech ETF's market cap, and Royal Bank of Canada pays a 2.66% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Bank of Canada for 47 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| RY | XBI | |
|---|---|---|
Market Cap | $262.99B | $10.11B |
Volume | 1,016,377 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $217.87 | $169.55 |
52-Week Low | $143.64 | $104.99 |
Typical Hold Time | 47 Days | 37 Days |
Enterprise Value | $730.11B | — |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $190.31, down 0.48% with a bearish technical signal despite strong fundamentals. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with a 32.01% net margin, while analyst consensus shows 43% buy ratings amid mixed sentiment.
RY presents a valuation disconnect with solid profitability (17.2% ROE) against bearish technicals. Investment opportunity lies in consistent earnings growth and dividend yield, though risks include stretched valuations and negative cash flow trends. The stock faces headwinds from technical indicators but maintains fundamental strength for long-term investors.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
